Clinical trial result
Merck’s Bold Bet: 6-Year Study on Oral PCSK9 Inhibitor Dominates Phase 3 Program
Anika Sharma
In the ever-evolving landscape of pharmaceutical breakthroughs, Merck & Co. has set its sights on a pioneering endeavor that could ...
Briqulimab Phase I Study Doses First Patient With Lower-Risk MDS
SG Tylor
Source – Jasper Therapeutics Jasper Therapeutics has initiated a Phase I trial (NCT05903274) to evaluate the use of briquilimab as ...
Adcetris Breakthrough: Six-Year Survival Data Reinforce Its Impact in Hodgkin Lymphoma Treatment
SG Tylor
Seagen has made a significant announcement regarding the updated U.S. Prescribing Information (PI) for Adcetris (brentuximab vedotin). The update includes ...
